Atara Biotherapeutics Stock News

A fatality in an early-stage clinical trial is weighing on the cell therapy company''s stock today.

Memorial Sloan Kettering Cancer Center''s (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patient in Phase 1 study of Atara Biotherapeutics Inc''s (NASDAQ: ATRA ) autologous mesothelin CAR T, ATA2271. MSK has voluntarily paused enrollment of new patients in the study temporarily while additional information regarding the case is gathered and reviewed. ATA2271 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin … Full story available on Benzinga.com

(Reuters) - Atara Biotherapeutics Inc said on Friday that enrolment in an early-stage study of its experimental cancer therapy had been paused after a patient died, sending shares of the drug developer down 12%. The trial testing the CAR-T cell therapy, ATA2271, was voluntarily paused by Atara''s partner, Memorial Sloan Kettering Cancer Center in New York, after a fatal serious adverse event. Atara said the institute has notified the U.S. Food and Drug Administration and is gathering more information about the case, with more updates expected in the coming weeks. CAR-T therapies work by harvesting a patient''s own disease-fighting T-cells, genetically engineering them to target specific proteins on cancer cells, and replacing them to seek out and attack cancer. The company said the first six patients enrolled in the two lowest dose groups had no serious toxicities that prevented an increase in dosage, and the patient who died was the first in a third, higher-dose cohort. (Reporting by Leroy Leo in Bengaluru; Editing by Amy Caren Daniel)

Atara (ATRA) is trading ~12% lower in the pre-market on Friday after the company reported a fatal serious adverse event (SAE) in a patient who received its experimental chimeric…

Memorial Sloan Kettering Cancer Center's (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patient in Phase 1 study of Atara Biotherapeutics Inc's (NASDAQ: ATRA)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2021 financial results after market close on Monday, February 28, 2022. Following the release, the Company will host a live conference call and we

FUJIFILM (FUJIY) is acquiring a cell therapy manufacturing facility from Atara Biotherapeutics (ATRA) for $100M.The Thousand Oaks, Calif.-based facility has the flexibility to produce

Atara Biotherapeutics Inc (ATRA) shares closed today 12.9% higher than it did at the end of yesterday. The stock is currently up 2.0% year-to-date, down 13.6% over the past 12 months, and up 8.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $16.23 and as low as $13.93 this week.Shares closed 26.5% below its 52-week high and 36.1% above its 52-week low.Trading volume this week was 33.5% lower than the 10-day average and 31.1% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -130.5% The company's stock price performance over the past 12 months beats the peer average by -71.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Atara Biotherapeutics Inc (ATRA) shares closed today 12.9% higher than it did at the end of yesterday. The stock is currently up 2.0% year-to-date, down 14.7% over the past 12 months, and up 8.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $16.23 and as low as $13.93 this week.Shares closed 26.5% below its 52-week high and 36.1% above its 52-week low.Trading volume this week was 34.6% lower than the 10-day average and 36.1% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -117.2% The company's stock price performance over the past 12 months beats the peer average by -52.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to

Atara Biotherapeutics <> announced a multi-year extension for its collaboration with Be The Match BioTherapies to source healthy donor cells for the off-the-shelf T-cell

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to